FerGene

FerGene is a biotechnology company focused on developing gene therapy treatments for bladder cancer, specifically targeting non-muscle invasive bladder cancer (NMIBC). As a spin-off of Ferring Pharmaceuticals, FerGene aims to commercialize nadofaragene firadenovec in the United States while advancing its global clinical development. The company seeks to leverage innovative science to transform the treatment landscape for bladder cancer, providing urologists with novel therapeutic options that harness the potential of gene therapy.